{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ba Z"],"funding":["Artificial Intelligence and Information Technology Application Fund of Fuwai Hospital and Chinese Academy of Medical Sciences","Noncommunicable Chronic Diseases-National Science and Technology Major Project","CAMS Innovation Fund for Medical Sciences","the National High Level Hospital Clinical Research Funding"],"pagination":["e105597"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12434780"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(9)"],"pubmed_abstract":["<h4>Introduction</h4>Effective secondary prevention of coronary heart disease (CHD) is often hindered by limited healthcare resources and poor patient adherence. We therefore developed an artificial intelligence (AI)-enhanced CHD management platform (AIM-CHD) that (i) automatically captures follow-up data through AI-driven voice calls, optical character recognition of laboratory reports and wearable sensor streams; (ii) enables closed-loop, automated risk factor management; and (iii) dynamically personalises follow-up intensity via continuously updated risk stratification and achievement of treatment targets. This trial aims to evaluate whether AIM-CHD improves risk factor control and reduces cardiovascular events compared with usual care.<h4>Methods and analysis</h4>In this prospective, single-centre, open-label, randomised controlled trial, 1100 CHD patients aged 18-85 years will be enrolled at Fuwai Hospital and randomised 1:1 to either the AIM-CHD group (n=550) or the usual care group (n=550) for a 3 month post-discharge intervention. The primary outcome is low-density lipoprotein cholesterol (LDL-C) level at 3 months. Secondary outcomes include target achievement for LDL-C and blood pressure, as well as glycosylated haemoglobin level, nonsmoking status, body mass index, composite cardiovascular endpoint and medication adherence.<h4>Ethics and dissemination</h4>Ethical approval was approved by the Ethics Committee of Fuwai Hospital on 4 November 2024 (2024-2422). The findings will be disseminated in peer-reviewed publications. An anonymised template of the written informed-consent form (Chinese and English versions) is available as Supplementary Material 1.<h4>Trial registration number</h4>ClinicalTrial, NCT06686056."],"journal":["BMJ open"],"pubmed_title":["Effectiveness of an AI-enhanced management system for coronary heart disease (AIM-CHD): rationale and design of a single-centre, open-label, randomised, parallel-controlled trial."],"pmcid":["PMC12434780"],"funding_grant_id":["2024-I2M-C&amp;T-B-040","2023ZD0504000","2024-GSP-GG-4","2024-AI22","2024-I2M-ZH-004"],"pubmed_authors":["Yang L","Liu M","Ba Z","Lian X","Chen G","Yu F","Zhao W","Yuan J","Zhao S","Zhang X","Wang X","Gao X","Su Y","Wang Z","Wu Y"],"additional_accession":[]},"is_claimable":false,"name":"Effectiveness of an AI-enhanced management system for coronary heart disease (AIM-CHD): rationale and design of a single-centre, open-label, randomised, parallel-controlled trial.","description":"<h4>Introduction</h4>Effective secondary prevention of coronary heart disease (CHD) is often hindered by limited healthcare resources and poor patient adherence. We therefore developed an artificial intelligence (AI)-enhanced CHD management platform (AIM-CHD) that (i) automatically captures follow-up data through AI-driven voice calls, optical character recognition of laboratory reports and wearable sensor streams; (ii) enables closed-loop, automated risk factor management; and (iii) dynamically personalises follow-up intensity via continuously updated risk stratification and achievement of treatment targets. This trial aims to evaluate whether AIM-CHD improves risk factor control and reduces cardiovascular events compared with usual care.<h4>Methods and analysis</h4>In this prospective, single-centre, open-label, randomised controlled trial, 1100 CHD patients aged 18-85 years will be enrolled at Fuwai Hospital and randomised 1:1 to either the AIM-CHD group (n=550) or the usual care group (n=550) for a 3 month post-discharge intervention. The primary outcome is low-density lipoprotein cholesterol (LDL-C) level at 3 months. Secondary outcomes include target achievement for LDL-C and blood pressure, as well as glycosylated haemoglobin level, nonsmoking status, body mass index, composite cardiovascular endpoint and medication adherence.<h4>Ethics and dissemination</h4>Ethical approval was approved by the Ethics Committee of Fuwai Hospital on 4 November 2024 (2024-2422). The findings will be disseminated in peer-reviewed publications. An anonymised template of the written informed-consent form (Chinese and English versions) is available as Supplementary Material 1.<h4>Trial registration number</h4>ClinicalTrial, NCT06686056.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-06-01T14:03:07.086Z","creation":"2026-04-08T13:16:15.386Z"},"accession":"S-EPMC12434780","cross_references":{"pubmed":["40953879"],"doi":["10.1136/bmjopen-2025-105597"]}}